aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma announced that its lead therapeutic candidate, efzofitimod, will be featured in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting in Boston, MA. The presentation, titled 'Efzofitimod for the Treatment of Pulmonary Sarcoidosis,' will be given by Dr. Daniel A. Culver on October 8, 2024. It will review data from a Phase 1b/2a study showing efzofitimod's ability to reduce steroid use while controlling symptoms in pulmonary sarcoidosis patients.
Efzofitimod is currently being investigated in the global Phase 3 EFZO-FIT™ study with 268 pulmonary sarcoidosis patients. Topline data is expected in Q3 2025. The drug is a first-in-class biologic immunomodulator designed to treat interstitial lung disease by modulating activated myeloid cells to resolve inflammation without immune suppression.
aTyr Pharma ha annunciato che il suo principale candidato terapeutico, efzofitimod, sarà presentato nella sessione Best of CHEST Journals al CHEST 2024 Annual Meeting a Boston, MA. La presentazione, intitolata 'Efzofitimod per il trattamento della sarcoidosi polmonare', sarà tenuta dal Dr. Daniel A. Culver l'8 ottobre 2024. Verranno esaminati i dati di uno studio di Fase 1b/2a che dimostra la capacità di efzofitimod di ridurre l'uso di steroidi mentre controlla i sintomi nei pazienti con sarcoidosi polmonare.
Attualmente, efzofitimod è oggetto di studio nel trial globale di Fase 3 EFZO-FIT™ con 268 pazienti affetti da sarcoidosi polmonare. I dati preliminari sono attesi nel terzo trimestre del 2025. Il farmaco è un immunomodulatore biologico di prima classe progettato per trattare le malattie polmonari interstiziali modulando le cellule mieloidi attivate per risolvere l'infiammazione senza soppressione immunitaria.
aTyr Pharma anunció que su candidato terapéutico principal, efzofitimod, se presentará en la sesión Best of CHEST Journals durante el CHEST 2024 Annual Meeting en Boston, MA. La presentación, titulada 'Efzofitimod para el Tratamiento de la Sarcoidosis Pulmonar', será realizada por el Dr. Daniel A. Culver el 8 de octubre de 2024. Se revisarán datos de un estudio de Fase 1b/2a que muestran la capacidad de efzofitimod para reducir el uso de esteroides mientras controla los síntomas en pacientes con sarcoidosis pulmonar.
Actualmente, efzofitimod se está investigando en el estudio global de Fase 3 EFZO-FIT™ con 268 pacientes con sarcoidosis pulmonar. Los datos iniciales se esperan para el tercer trimestre de 2025. El medicamento es un inmunomodulador biológico de primera clase diseñado para tratar la enfermedad pulmonar intersticial mediante la modulación de células mieloides activadas para resolver la inflamación sin suprimir el sistema inmunitario.
aTyr Pharma는 주요 치료 후보물질인 efzofitimod가 CHEST 2024 연례 회의에서 Best of CHEST Journals 세션에 소개될 것임을 발표했습니다. 'Efzofitimod for the Treatment of Pulmonary Sarcoidosis'라는 제목의 발표는 2024년 10월 8일 Daniel A. Culver 박사가 진행할 예정입니다. 이 발표에서는 efzofitimod가 폐사르코이드 환자에서 증상을 조절하면서 스테로이드 사용을 줄이는 능력을 보여주는 1b/2a 단계 연구 데이터를 검토할 것입니다.
efzofitimod는 현재 268명의 폐사르코이드 환자를 대상으로 하는 전세계 3상 EFZO-FIT™ 연구에서 조사되고 있습니다. 주목할 만한 데이터는 2025년 3분기에 발표될 예정입니다. 이 약물은 염증을 해결하기 위해 활성화된 골수세포를 조절하여 면역 억제 없이 간질성 폐질환을 치료하도록 설계된 최초의 생물학적 면역조절제입니다.
aTyr Pharma a annoncé que son principal candidat thérapeutique, efzofitimod, sera présenté lors de la session Best of CHEST Journals à CHEST 2024 Annual Meeting à Boston, MA. La présentation, intitulée 'Efzofitimod pour le traitement de la sarcoïdose pulmonaire', sera assurée par le Dr Daniel A. Culver le 8 octobre 2024. Elle examinera les données d'une étude de phase 1b/2a montrant la capacité d'efzofitimod à réduire l'utilisation de stéroïdes tout en contrôlant les symptômes chez les patients atteints de sarcoïdose pulmonaire.
efzofitimod est actuellement investigué dans l'étude mondiale de phase 3 EFZO-FIT™ avec 268 patients atteints de sarcoïdose pulmonaire. Les données préliminaires sont attendues pour le troisième trimestre de 2025. Ce médicament est un immunomodulateur biologique de première classe conçu pour traiter les maladies pulmonaires interstitielles en modulant les cellules myéloïdes activées pour résoudre l'inflammation sans suppression immunitaire.
aTyr Pharma hat bekannt gegeben, dass sein führender therapeutischer Kandidat, efzofitimod, in der Best of CHEST Journals-Sitzung beim CHEST 2024 Annual Meeting in Boston, MA, vorgestellt wird. Die Präsentation mit dem Titel 'Efzofitimod zur Behandlung der pulmonalen Sarkoidose' wird am 8. Oktober 2024 von Dr. Daniel A. Culver gehalten. Dabei werden Daten aus einer Phase 1b/2a-Studie präsentiert, die die Fähigkeit von efzofitimod zeigt, den Steroidverbrauch zu reduzieren, während es die Symptome bei Patienten mit pulmonaler Sarkoidose kontrolliert.
efzofitimod wird derzeit in der globalen Phase 3 EFZO-FIT™-Studie mit 268 Patienten mit pulmonaler Sarkoidose untersucht. Die vorläufigen Daten werden im dritten Quartal 2025 erwartet. Das Medikament ist ein biologisches Immunmodulator der ersten Klasse, das zur Behandlung von interstitielle Lungenerkrankungen entwickelt wurde, indem es aktivierte myeloische Zellen moduliert, um Entzündungen ohne Immunsuppression zu lösen.
- Efzofitimod selected for prestigious Best of CHEST Journals session, indicating high-quality data
- Phase 1b/2a study showed efzofitimod's ability to reduce or eliminate steroid use while controlling symptoms
- Ongoing global Phase 3 EFZO-FIT™ study with 268 patients for pulmonary sarcoidosis
- Efzofitimod is a first-in-class biologic immunomodulator with potential to treat interstitial lung disease
- Topline data from Phase 3 study not expected until Q3 2025, indicating a long wait for potential market approval
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company’s lead therapeutic candidate, efzofitimod, will be featured in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting, which is scheduled to take place October 6 – 9, 2024, in Boston, MA.
“We are very pleased to have efzofitimod featured in this year’s Best of CHEST session, which speaks to the high quality of the data from the Phase 1b/2a study that was previously published in the journal,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We believe the findings from this study, which showed the ability of efzofitimod to reduce—and in some cases eliminate— steroid use in patients while controlling symptoms, are an important step forward in developing a potential new treatment for sarcoidosis.”
Details of the presentation appears below.
Title: Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Presenter: Daniel A. Culver, D.O., Chair of the Division of Pulmonary Medicine, Cleveland Clinic
Session Title: Best of CHEST Journals, Presented by CHEST, CHEST Critical Care, and CHEST Pulmonary
Date and Time: Tuesday, October 8, 2024, from 4:00 p.m. to 4:20 p.m. EDT
Location: Convention Center 256
The presentation will review data supporting the efficacy of efzofitimod in pulmonary sarcoidosis, including findings from a Phase 1b/2a study for key efficacy endpoints including measures of steroid reduction, lung function, sarcoidosis symptoms and inflammatory biomarkers that were published in CHEST and a post hoc analysis of the Phase 1b/2a study that evaluated time-to-first-relapse and relapse rate for steroid use that was published in the European Respiratory Journal.
Efzofitimod is currently being investigated in the global pivotal Phase 3 EFZO-FIT™ study in 268 patients with pulmonary sarcoidosis. Topline data from the study are expected in the third quarter of 2025.
About Efzofitimod
Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as "anticipate," “believes,” “designed,” “can,” “expects,” “intends,” “may,” “plans,” “potential,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the clinical development for efzofitimod, including the potential of efzofitimod to reduce or eliminate steroid use in patients while controlling symptoms and the potential for efzofitimod to be a new treatment for sarcoidosis. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations, strategies or prospects will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of efzofitimod, risks associated with clinical trials and their resulting data generally, the risk that we or our partners may cease or delay preclinical or clinical development activities for efzofitimod for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
What is the main focus of aTyr Pharma's CHEST 2024 presentation on efzofitimod?
When and where will aTyr Pharma's efzofitimod be presented at CHEST 2024?
What is the current stage of clinical development for aTyr Pharma's efzofitimod (ATYR stock)?
How does aTyr Pharma's efzofitimod work in treating interstitial lung disease?
